Advertisement

 

 

Familial MTC with RET exon 8 Gly533Cys mutation: origin and prevalence of second malignancy.

Familial MTC with RET exon 8 Gly533Cys mutation: origin and prevalence of second malignancy.
Author Information (click to view)

Saltiki K, Anagnostou E, Simeakis G, Kouki S, Angelopoulou A, Sarika L, Papathoma A, Alevizaki M,


Saltiki K, Anagnostou E, Simeakis G, Kouki S, Angelopoulou A, Sarika L, Papathoma A, Alevizaki M, (click to view)

Saltiki K, Anagnostou E, Simeakis G, Kouki S, Angelopoulou A, Sarika L, Papathoma A, Alevizaki M,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Endocrine connections 2017 09 266(8) 676-684 doi 10.1530/EC-17-0147

Abstract
INTRODUCTION
High prevalence of RET p.Gly533Cys (c.1597G > T) has been found in familial MTC in Greece (exon 8 fMTC). We studied their origin and compared clinical characteristics with non-exon 8 fMTC.

METHODS
102 fMTC (FMTC and MEN2A) patients (31.4% males) were followed for 2.9-37 years (median 6 years). Fifty-one carried the RET exon 8 mutation; the remaining were non-exon 8 fMTC (exons 10, 11, 13, 14). Pre-, post-operative calcitonin, disease extent at diagnosis and follow-up and families’ place of origin were recorded.

RESULTS
Exon 8 fMTC were older (42.3 ± 13.3 vs 30.8 ± 17.8 years, P < 0.001), including index cases (P = 0.016). In index cases, the stage at diagnosis was more favorable in exon 8 fMTC compared to non-exon 8 fMTC (stage I and II: 65% vs 23.8%, stage III: 25% vs 57.1%, stage IV: 10% vs 19%, P = 0.025). More favorable outcome was noted in exon 8 fMTCs (remission: 72.5% vs 45.8%, stable disease: 27.5% vs 41.7%, progression: 0.0% vs 12.5%, P = 0.001). Exon 8 fMTC patients carried more frequently a second malignancy (25.5% vs 6.3%, P = 0.009); 69% of these were PTCs. Exon 8 fMTC patients were significantly older at diagnosis compared to non-exon 8 moderate-risk RET carriers and presented more favorable clinical outcome (remission: 72.5% vs 50%, stable disease: 27.5% vs 41.7%, progression: 0.0% vs 8.3%, P = 0.021). This difference remained when only index cases were analyzed. 'Hot spots' in the origin of exon 8 fMTCs families were recognized. No phenotype or outcome differences were found between the exon 8 families from the various regions. CONCLUSIONS
In exon 8 fMTCs’ older age, favorable disease stage at diagnosis and favorable outcome suggest slow disease progression compared to non-exon 8 fMTC. Compared with moderate-risk RET mutation carriers, exon 8 fMTC patients have a more favorable clinical outcome. The higher prevalence of second malignancies, especially PTC, not previously reported, merits further investigation. Increased awareness for inherited disease is required for patients with apparently sporadic MTC originating from recognized ‘hot spots’, as the age at presentation is usually delayed.

Submit a Comment

Your email address will not be published. Required fields are marked *

11 + 16 =

[ HIDE/SHOW ]